PolyPeptide Group's earnings have been declining at an average annual rate of -57.6%, while the Life Sciences industry saw earnings growing at 4.9% annually. Revenues have been growing at an average rate of 8.7% per year.
Key information
-57.58%
Earnings growth rate
-58.20%
EPS growth rate
Life Sciences Industry Growth
36.86%
Revenue growth rate
8.71%
Return on equity
-6.22%
Net Margin
-5.44%
Next Earnings Update
13 Aug 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How PolyPeptide Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
LSE:0AAJ Revenue, expenses and earnings (EUR Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
389
-21
56
2
30 Sep 25
379
-28
52
2
30 Jun 25
369
-35
49
2
31 Mar 25
353
-27
46
1
31 Dec 24
337
-20
44
1
30 Sep 24
330
-24
44
1
30 Jun 24
324
-29
43
1
31 Mar 24
322
-40
42
1
31 Dec 23
320
-51
42
1
30 Sep 23
300
-44
41
1
30 Jun 23
279
-37
40
1
31 Mar 23
280
-14
40
1
31 Dec 22
281
8
41
1
30 Sep 22
281
20
40
1
30 Jun 22
281
33
40
1
31 Mar 22
281
40
36
1
31 Dec 21
282
47
32
1
30 Sep 21
277
48
31
1
30 Jun 21
271
48
29
1
31 Mar 21
248
40
28
1
31 Dec 20
224
31
28
1
31 Dec 19
203
26
25
1
31 Dec 18
181
24
24
12
Quality Earnings: 0AAJ is currently unprofitable.
Growing Profit Margin: 0AAJ is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0AAJ is unprofitable, and losses have increased over the past 5 years at a rate of 57.6% per year.
Accelerating Growth: Unable to compare 0AAJ's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0AAJ is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (5.4%).
Return on Equity
High ROE: 0AAJ has a negative Return on Equity (-6.22%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/30 13:05
End of Day Share Price
2026/05/29 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PolyPeptide Group AG is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.